These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 562482)

  • 21. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversibility of the interaction of CGP 11305 A with MAO A in vivo.
    Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E
    Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition by clorgyline and deprenyl of the different forms of monoamine oxidase in rat liver mitochondria.
    Egashira T; Ekstedt B; Oreland L
    Biochem Pharmacol; 1976 Dec; 25(23):2583-6. PubMed ID: 985579
    [No Abstract]   [Full Text] [Related]  

  • 24. Are there MAO inhibitors specific for dopamine metabolism?
    Youdim MB; Holzbauer M
    Adv Biochem Psychopharmacol; 1977; 16():349-58. PubMed ID: 329649
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of clorgyline and (-)deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein.
    Caramona MM; Osswald W
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):396-400. PubMed ID: 3921855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC; Delini-Stula A; Maître L
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the new 5-HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4,alpha-dimethyl-7-tyramine (H 77/77).
    Lassen JB
    Psychopharmacology (Berl); 1978 Apr; 57(2):151-3. PubMed ID: 418448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ; Oreland L; Callingham BA
    J Pharm Pharmacol; 1981 Jun; 33(6):341-7. PubMed ID: 6115003
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice.
    Boden R; Botting R; Coulson P; Spanswick G
    Br J Pharmacol; 1984 May; 82(1):151-4. PubMed ID: 6428496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats.
    Knoll B; Held G; Gyarmati Z
    Pol J Pharmacol Pharm; 1977; 29(3):291-6. PubMed ID: 887504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks.
    Barbelivien A; Nyman L; Haapalinna A; Sirviö J
    Pharmacol Toxicol; 2001 Jun; 88(6):304-12. PubMed ID: 11453370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of monoamine oxidase inhibitors and dopamine agonists on the behavior of mammal- and frog-eating snakes.
    Temple JG; Barthalmus GT
    Physiol Behav; 1994 May; 55(5):927-33. PubMed ID: 7912837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum.
    Kitanaka N; Kitanaka J; Takemura M
    Neuroscience; 2005; 130(2):295-308. PubMed ID: 15664686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
    Braestrup C; Andersen H; Randrup A
    Eur J Pharmacol; 1975 Nov; 34(1):181-7. PubMed ID: 1241962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR; Zreika M; Robin M; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.
    Graham D; Tahraoui L; Langer SZ
    Neuropharmacology; 1987 Aug; 26(8):1087-92. PubMed ID: 2958720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.